Ilett Elizabeth J
Leeds Institute of Medical Research at St James', St James' University Hospital, Leeds, UK.
Methods Mol Biol. 2020;2058:229-236. doi: 10.1007/978-1-4939-9794-7_14.
Oncolytic virus therapy is a rapidly expanding branch of cancer immunotherapy and represents a genuine opportunity to improve currently available treatment options. However, as single agents oncolytic viruses have shown only moderate clinical benefit and many challenges remain before their full potential is realized. Central to this is the efficient delivery of the virus to the tumor site and potentiation of the antitumor immune response. This chapter describes the loading of oncolytic reovirus onto monocytes which act as carriers for delivery of the virus to the tumor site and, as antigen presenting cells, may also thereby potentiate the development of an adaptive antitumor immune response.
溶瘤病毒疗法是癌症免疫疗法中一个迅速发展的分支，代表了改善现有治疗方案的真正机会。然而，作为单一药物，溶瘤病毒仅显示出适度的临床益处，在实现其全部潜力之前仍存在许多挑战。其中的核心问题是如何将病毒有效地递送至肿瘤部位，并增强抗肿瘤免疫反应。本章描述了将溶瘤呼肠孤病毒加载到单核细胞上的过程，单核细胞作为病毒载体将其递送至肿瘤部位，并且作为抗原呈递细胞，还可能增强适应性抗肿瘤免疫反应的发展。
